1. National Breast Cancer Centre**. Clinical practice guidelines for the management of early breast cancer (2nd Edition). Canberra: Commonwealth of Australia, 2001.
2. National Breast and Ovarian Cancer Centre**. Follow-up of patients with early breast cancer: a systematic review. NBOCC**, Surry Hills, NSW, 2009.
3. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra: Commonwealth of Australia, 2000.
4. Montgomery DA, Krupa K and Cooke TG. Follow-up in breast cancer: Does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007; 97(12):1632-41.
5. de Bock GH, Bonnema J, van der Hage J, Kievit J and van de Velde CJ. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol. 2004;22(19):4010-8.
6. Donnelly J, Mack P and Donaldson LA. Follow-up of breast cancer: time for a new approach? Int J Clin Pract. 2001;55(7):431-3.
7. Hiramanek N. Breast cancer recurrence: Follow-up after treatment for primary breast cancer. Postgrad Med J. 2004;80(941):172-6.
8. Perrone MA, Musolino A, Michiara M, et al. Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase. Tumori. 2004;90(3):276-9.
9. Te Boekhorst DS, Peer NG, Van der Sluis RF, Wobbes T and Ruers TJ. Periodic follow-up after breast cancer and the effect on survival. Eur J Surg. 2001;167(7):490-6.
10. Montgomery DA, Krupa K, Jack WJ, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer. 2007;96(12):1802-7.
11. Kollias J, Evans AJ, Wilson AR, et al. Value of contralateral surveillance mammography for primary breast cancer follow-up. World J Surg. 2000;24(8):983-7; discussion 8-9.
12. Robinson A, Speers C, Olivotto I and Chia S. Method of detection of new contralateral primary breast cancer in younger versus older women. Clin Breast Cancer. 2007;7(9):705-9.
13. Kaas R, Hart AA, Besnard AP, Peterse JL and Rutgers EJ. Impact of mammographic interval on stage and survival after the diagnosis of contralateral breast cancer. Br J Surg. 2001;88(1):123-7.
14. Kokko R, Hakama M and Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: A randomized trial. Breast Cancer Res Treat. 2005;93(3):255-60.
15. Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol. 2006;24(6):848-55.
16. Koinberg I, Fridlund B, Engholm G and Holmberg L. Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study. Eur J Oncol Nurs. 2004;8(2):109-20.
17. Brown L, Payne S and Royle G. Patient initiated follow-up of breast cancer. Psycho Oncol. 2002;11(4):346-55.
18. Koinberg I, Langius-Eklof A, Holmberg L and Fridlund B. The usefulness of a multidisciplinary educational programme after breast cancer surgery: a prospective and comparative study. Eur J Oncol Nurs. 2006;10(4):273-82.
19. National Breast Cancer Centre**. Multidisciplinary meetings for cancer care: a guide for health service providers. NBCC**, Camperdown, NSW, 2005.
20. National Breast Cancer Centre** and National Health and Medical Research Council. Psychosocial clinical practice guidelines: information, support and counselling for women with early breast cancer Canberra, ACT, 2000.
21. National Breast Cancer Centre**. Clinical practice guidelines for the psychosocial care of adults with cancer. NBCC**, Camperdown, NSW, 2003.
22. McCaughan E and McSorley O. Consumers and professionals perceptions of a breast cancer review clinic. J Adv Nurs. 2007;60(4):419-26.
23. Kelly L, Caldwell K and Henshaw L. Involving users in service planning: a focus group approach. Eur J Oncol Nurs. 2006;10(4):283-93.
24. Beaver K and Luker KA. Follow-up in breast cancer clinics: reassuring for patients rather than detecting recurrence. Psycho Oncol. 2005;14(2):94-101.
25. Gaudine A, Sturge-Jacobs M and Kennedy M. The experience of waiting and life during breast cancer follow-up. Res Theory Nurs Pract. 2003;17(2):153-68.
26. Allen A. The meaning of the breast cancer follow-up experience for the women who attend. Eur J Oncol Nurs. 2002;6(3):155-61.
27. Jiwa M, Thompson J, Coleman R and Reed M. Breast cancer follow-up: Could primary care be the right venue? Curr Med Res Opin. 2006;22(4):625-30.
28. Renton JP, Twelves CJ and Yuille FAP. Follow-up in women with breast cancer: The patient s perspective. Breast. 2002;11(3):257-61.
29. Pennery E and Mallet J. A preliminary study of patients perceptions of routine follow-up after treatment for breast cancer. Eur J Oncol Nurs. 2000;4(3):138-45; discussion 46-7.
30. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2000;-(4):CD001768.
31. National Institute for Clinical Excellence. Early and locally advanced breast cancer: diagnosis and treatment. Draft for consultation, August 2008 UK, 2008.
32. Grogan M, Rangan A, Gebski V and Boyages J. The value of follow-up of patients with early breast cancer treated with conservative surgery and radiation therapy. Breast. 2002;11(2):163-9.
33. Chen C, Orel SG, Hams EE, Hwang WT and Solih LJ. Relation between the method of detection of initial breast carcinoma and the method of detection of subsequent ipsilateral local recurrence and contralateral breast carcinoma. Cancer. 2003;98(8):1596-602.
34. Yau TK, Sze H, Soong IS, et al. Surveillance mammography after breast conservation therapy in Hong Kong: Effectiveness and feasibility of risk-adapted approach. Breast. 2007:doi:10.1016/j.breast.2007.08.001.
35. Doyle T, Schultz DJ, Peters C, Harris E and Solin LJ. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2001;51(1):74-80.
36. Anan K, Mitsuyama S, Tamae K, et al. Postoperative follow-up of patients with early breast cancer: Reappraisal of serum tumor markers. Surg Today. 2002;32(1):13-8.
37. Kokko R, Holli K and Hakama M. CA 15-3 in the follow-up of localised breast cancer: A prospective study. Eur J Cancer. 2002;38(9):1189-93.
38. Nakamura T, Kimura T, Umehara Y, et al. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Surg Today. 2005;35(1):19-21.
39. Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269 doi:10.1186/471-2407-6-269.
40. Valenzuela P, Mateos S, Tello E, et al. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol. 2003;24(1):60-2.
41. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol. 2007;25(33):5287-312.
42. Schootman M, Jeffe DB, Lian M, Aft R and Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111(3): 489-96.
43. Lash TL, Fox MP, Buist DS, et al. Mammography surveillance and mortality in older breast cancer survivors. J Clin Oncol. 2007;25(21):3001-6.
44. Lash TL, Fox MP and Silliman RA. Reduced mortality rate associated with annual mammograms after breast cancer therapy. Breast J. 2006;12(1):2-6.
45. de Bock GH, Bonnema J, Zwaan RE, et al. Patients needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer. 2004;90(6):1144-50.
46. Donnelly P, Hiller L, Bathers S, Bowden S and Coleman R. Questioning specialists attitudes to breast cancer follow-up in primary care. Ann Oncol. 2007;18(9):1467-76.
47. Vassilopoulou-Sellin R and Klein MJ. Health care priorities for menopausal women with a history of breast cancer. South Med J. 2002;95(11):1269-75.
48. Oltra A, Santaballa A, Munarriz B, Pastor M and Montalar J. Cost-benefit analysis of a follow-up program in patients with breast cancer: A randomized prospective study. Breast J. 2007;13(6):571-4.
49. Bornhak S, Heidemann E, Herschlein HJ, et al. Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study. Onkologie. 2007; 30(8-9):443-9.
50. Kokko R, Hakama M and Holli K. Role of chest X-ray in diagnosis of the first breast cancer relapse: a randomized trial. Breast Cancer Res Treat. 2003;81:33-9.
51. Etim AE, Schellhase KG, Sparapani R and Nattinger AB. Effect of model of care delivery on mammography use among elderly breast cancer survivors. Breast Cancer Res Treat. 2006;96(3):293-9.
52. Nissen MJ, Beran MS, Lee MW, et al. Views of primary care providers on follow-up care of cancer patients. Fam Med. 2007;39(7):477-82.
53. National Breast Cancer Centre**. Multidisciplinary Care (MDC) in Australia a four-page brochure summary NBCC**, Camperdown, NSW, 2005.
54. Koinberg I, Holmberg L and Fridlund B. Satisfaction with routine follow-up visits to the physician: The needs of patients with breast cancer. Acta Oncol. 2001;40(4):454-9.
55. Miedema B, MacDonald I and Tatemichi S. Cancer follow-up care: Patients perspective. Can Fam Physician. 2003;49(July):890-5.
56. National Breast and Ovarian Cancer Centre**. Review of research evidence on secondary lymphoedema: incidence, prevention, risk factors and treatment. NBOCC** Surry Hills, NSW, 2008.
57. National Breast and Ovarian Cancer Centre**. The management of secondary lymphoedema a guide for health professionals NBOCC** Surry Hills, NSW, 2008.
58. National Breast Cancer Centre**. Recommendations for aromatase inhibitors as adjuvant endocrine therapy for post-menopausal women with hormone receptor-positive early breast cancer. NBCC** Camperdown, NSW, 2006.
59. National Breast Cancer Centre**. Recommendations for use of Trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer. NBCC** Camperdown, NSW, 2007.
60. Holmes MD, Chen WY, Feskanich D, and et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20):2479-86.
61. Chlebowski RT., Blackburn GL., Thomson CA., Nixon DW. and Shapiro A. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women s Intervention Nutrition Study. JNCI. 2006;98(24):1767-76.
62. McNeely ML., Campbell KL., Rowe BH., et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175(1):34-41.
63. Current Controlled trials ISRCTN74071417. http://isrctn.org/ISRCTN74071417. Accessed: 7th February 2008.
64. Kimman ML, Voogd AC, Dirksen CD, et al. Improving the quality and efficiency of follow-up after curative treatment for breast cancer Rationale and study design of the MaCare trial. BMC Cancer. 2007;7:1 doi:10.1186/471-2407-7-1.
65. Current Controlled trials ISRCTN86567908. http://www.controlled-trials.com/ISRCTN8656790 Accessed: 7th February 2008.
** In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.